“…So far, all the previously reported DON-MAbs were selected by homologous screening and most of them displayed much higher affinity either to 3-acetyl-DON (3-ADON) (Baumgartner et al, 2010;Casale et al, 1988;Maragos and McCormick, 2000;Tangni et al, 2010) or to 15-acetyl-DON (15-ADON) (Dos Santos et al, 2011;Maragos et al, 2011;Nicol et al, 1993;Sinha et al, 1995;Xu et al, 2010), the two derivatives that often co-occur with DON. Thus, the relevant immunoassays could only be used to screen for DON/3-ADON or DON/15-ADON, not three of them simultaneously.…”